Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

Nature Reviews Clinical Oncology, Published online: 22 March 2022; doi:10.1038/s41571-022-00607-3Chimeric antigen receptor T cells have revolutionized the treatment of patients with certain haematological malignancies. Nonetheless, an optimal approach to lymphodepleting chemotherapy and/or bridging therapies has yet to be defined in patients receiving these agents. In this Review, the authors describe the various lymphodepletion and/or bridging therapy strategies used, and highlight the need for prospective comparisons in order to determine the safest and most effective approach.

Source: Nature Reviews Clinical Oncology - March 22, 2022 Category: Cancer & Oncology Authors: Leila Amini Sara K. Silbert Shannon L. Maude Loretta J. Nastoupil Carlos A. Ramos Renier J. Brentjens Craig S. Sauter Nirali N. Shah Mohamed Abou-el-Enein Source Type: research